Gelonghui, January 25 | Yingke Healthcare (300677.SZ) announced that in order to further optimize the investment structure and enhance investment value, Inke Medical Technology Co., Ltd. plans to sign the “Haining Qingling Venture Capital Fund Partnership (Limited Partnership) Partnership Agreement” with Shanghai Rongxi Venture Capital Management Co., Ltd. (“Shanghai Rongxi”) to participate in investing in Haining Qingling Venture Capital Fund Partnership (limited partnership) (tentative name, subject to industrial and commercial approval, abbreviated as “partnership”, “fund” or “fund”). The total amount of capital pledged by the partnership is no more than 100 million yuan (the currency is RMB, same below), of which the company will pledge 20 million yuan as the limited partner (LP) of the partnership.
The scope of investment of the fund includes hard technology enterprises represented by the military and aerospace industries; high-tech enterprises represented by new materials and fine chemicals, clean energy and environmental protection, and next-generation information technology; and the big health industry represented by medical devices and biomedicine.